2023
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosis
2021
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
Shallis RM, Wang R, Bewersdorf JP, Zeidan AM, Davidoff AJ, Huntington SF, Podoltsev NA, Ma X. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Therapeutic Advances In Hematology 2021, 12: 20406207211043404. PMID: 35154624, PMCID: PMC8832334, DOI: 10.1177/20406207211043404.Peer-Reviewed Original ResearchChronic phase chronic myeloid leukemiaFrontline tyrosine kinase inhibitorsTyrosine kinase inhibitorsOlder patientsChronic myeloid leukemiaTKI switchingMyeloid leukemiaSecond-generation tyrosine kinase inhibitorsBCR-ABL1 tyrosine kinase inhibitorsTyrosine kinase inhibitor useOlder CML patientsEnd Results-MedicareFavorable safety profileSpecific patient populationsContemporary practice patternsFrontline imatinibTKI choiceGreater comorbidityMost patientsInhibitor usePatient characteristicsWhite patientsDiagnosis yearTKI useCML patients
2020
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved
Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews 2020, 47: 100773. PMID: 33213985, DOI: 10.1016/j.blre.2020.100773.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid sarcomaAllogeneic hematopoietic cell transplantWorld Health Organization classificationAcute myeloid leukemia tumorsLeukemia tumorsOutcomes of patientsPost-remission therapyHematopoietic cell transplantMedian latency periodIndependent prognostic impactBone marrow evaluationAnti-leukemia therapyPET/CTCellular adhesion moleculesPatient characteristicsPrognostic impactLocal therapyCell transplantMarrow evaluationOrganization classificationConventional chemotherapyMyeloid leukemiaTherapeutic approachesReceptor/ligand